Long-term follow-up of children with acute promyelocytic leukemia treated with Beijing Children’s Hospital APL 2005 protocol (BCH-APL 2005)
暂无分享,去创建一个
J. Xie | G. Feng | Min-Yuan Wu | Huyong Zheng | Wei Lin | Yuanyuan Zhang | Linya Wang | Ruidong Zhang | Peijing Qi | Hui-wen Shi | Ying Wu | Jiaole Yu | Jia Fan | P. Qi | Jing Xie | Ruidong Zhang | Ruidong Zhang | Ruidong Zhang | Ruidong Zhang
[1] R. Foà,et al. Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL. , 2018, Blood.
[2] H. Dombret,et al. Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group , 2018, Haematologica.
[3] Xiao-jun Huang,et al. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial. , 2018, The Lancet. Oncology.
[4] J. Krosl,et al. Transcriptomic landscape of acute promyelocytic leukemia reveals aberrant surface expression of the platelet aggregation agonist Podoplanin , 2018, Leukemia.
[5] V. Kota,et al. The global problem of early deaths in acute promyelocytic leukemia: A strategy to decrease induction mortality in the most curable leukemia. , 2017, Blood reviews.
[6] E. Estey,et al. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. , 2017, Blood.
[7] A. Levis,et al. PML–RARα kinetics and impact of FLT3–ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy , 2016, Leukemia.
[8] F. Lo‐Coco,et al. Current management of newly diagnosed acute promyelocytic leukemia. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] R. Schlenk,et al. Targeted Therapy Alone for Acute Promyelocytic Leukemia. , 2016, The New England journal of medicine.
[10] R. Hills,et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. , 2015, The Lancet. Oncology.
[11] Z. Chen,et al. Synergistic targeted therapy for acute promyelocytic leukaemia: a model of translational research in human cancer , 2015, Journal of internal medicine.
[12] M. Breccia,et al. FLT3-ITD in acute promyelocytic leukemia: clinical distinct profile but still controversial prognosis. , 2015, Leukemia research.
[13] P. Miljić,et al. Thrombotic events in acute promyelocytic leukemia. , 2015, Thrombosis research.
[14] Xiao-jun Huang,et al. Oral arsenic and retinoic acid for high-risk acute promyelocytic leukemia , 2014, Journal of Hematology & Oncology.
[15] H. Dombret,et al. Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients , 2014, Leukemia.
[16] S. Adil,et al. Clinical characteristics, outcome and early induction deaths in patients with acute promyelocytic leukaemia: a five-year experience at a tertiary care centre. , 2014, Singapore medical journal.
[17] J. Feusner,et al. Treatment of paediatric APL: how does the therapeutic approach differ from adults? , 2014, Best practice & research. Clinical haematology.
[18] R. Ribeiro,et al. How I treat children and adolescents with acute promyelocytic leukaemia , 2014, British journal of haematology.
[19] B. B. Weitner,et al. Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death. , 2013, Leukemia research.
[20] Paola Fazi,et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. , 2013, The New England journal of medicine.
[21] Saijuan Chen,et al. Targeting agents alone to cure acute promyelocytic leukemia. , 2013, The New England journal of medicine.
[22] H. Dombret,et al. Outcome of acute promyelocytic leukemia (APL) in children and adolescents: an analysis in two consecutive trials of the European APL Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] F. Lo‐Coco,et al. Modern approaches to treating acute promyelocytic leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] G. Henze,et al. Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses , 2010, British journal of haematology.
[25] E. Estey,et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] J. Esteve,et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. , 2009, Blood.
[27] Zhen-yi Wang,et al. Acute promyelocytic leukemia: from highly fatal to highly curable. , 2008, Blood.
[28] R. Foà,et al. GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. , 2005, Blood.
[29] J. Miguel,et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. , 1999, Blood.
[30] Zi X. Chen,et al. A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. , 1991, Blood.
[31] E. Dmitrovsky,et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). , 1991, The New England journal of medicine.
[32] R Berger,et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. , 1990, Blood.
[33] Zhen-yi Wang,et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. , 1988, Haematology and blood transfusion.
[34] F. Appelbaum,et al. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. , 2000, Blood.